ABOUT EVENT
The 3rd Hippo Pathway Targeted Drug Development Summit
The Hippo signaling pathway and its role in mesothelioma has been known for a while, but it is only recently that the industry has started to delve into targeting novel targets in the Hippo pathway and create combinations with existing small molecule inhibitors.
The 3rd Hippo Pathway Targeted Drug Development Summit came to the comfort of your screens in November 2024, gathering industry heavyweights such as Vivace Therapeutics, Orion Pharma, BridGene Biosciences, and Insilico Medicine, along with exciting new players like Etern Therapeutics, Crossignal Therapeutics, and Tyk Medicines, to bring you the bleeding edge of the Hippo pathway drug industry.
It was your exclusive opportunity to learn about the latest advances in the Hippo industry, from the latest clinical readouts to novel combination strategies with RAS, EGFR, and MAPK pathway drugs.
In 2024, Your Peers Came Together To:
Overcome Off
Target Toxicity
and optimize their
patient selection
as they accessed
the latest clinical
data from drugs
targeting the Hippo
pathway from the
likes of Vivace
Therapeutics
& Crossignal
Therapeutics
Accelerate the IND
Enabling Process
with exciting
case studies on
in vivo efficacy
in mesothelioma
models and
immunotherapy
combinations
with Insilico
Medicine, Tyk
Medicines, Etern
Therapeutics and
more
Achieve Sustained
Inhibition of the
Hippo pathway
through novel
covalent drugs and
targeted degraders
developed
by BridGene
Bioscience,
University of
Florida and more
Realize the
Potential of Novel
Combination
Strategies as
they unravelled Hippo
driven resistance
mechanisms
against KRAS,
MAPK and EGFR
inhibitors with
the University of
Toledo, University
of Torino and more
Reliably Predict
Clinical Outcomes
through fit for
purpose preclinical
models developed
at the Albany
Medical College,
University of
Edinburgh
and Cleveland
Clinic that will help
them accurately
determine patient
sensitivity to your
Hippo drugs
Who Would You Have Met Virtually?
Attendees were able to meet with all the key decision makers in the Hippo space, including CXOs, Heads and Directors of drug discovery, translational oncology, and clinical development.
This niche community came together over 2 days to advance the field and discuss next generation therapeutics. This gathering of Hippo drug developers, small molecule experts and key opinion leaders from academia was your perfect opportunity to assess the field, take back actionable insights to your team, and realize the potential of your Hippo pathway targeted drugs.
Companies on the Program:
What Your Peers Have to Say:
“Great to see this series of Meeting on Hippo-Yap. It’s important to share/exchange ideas with peers to advance drug development around this important pathway using this forum.” – Founder & CEO, Crossignal Therapeutics
“Opportunity to share our research and experiences with VT3989, contributing to the broader knowledge base and receiving feedback from peers. Engage in discussions that may provide new perspectives or innovative approaches to push the field forward. Connect with leading researchers, clinicians, and industry experts who are focused on the development and therapeutic application of TEAD inhibitors. Build relationships that may lead to future collaborations or partnerships in research and development.” – Chief Medical Officer, Vivace Therapeutics
“Hanson Wade always organizes scientific meetings at the cutting edge of Molecular Oncology, with intense networking between academia and industry.” – Professor, University of Torino